Chong Kun Dang Holdings Corp. (KRX:001630)
South Korea
· Delayed Price · Currency is KRW 44,150
-450 (-1.01%)
At close: Apr 16, 2025, 3:30 PM KST
Chong Kun Dang Holdings Revenue
In the year 2024, Chong Kun Dang Holdings had annual revenue of 957.75B KRW with 8.86% growth. Chong Kun Dang Holdings had revenue of 227.07B in the quarter ending December 31, 2024, with 1.09% growth.
Revenue
957.75B
Revenue Growth
+8.86%
P/S Ratio
0.64
Revenue / Employee
25.89B
Employees
37
Market Cap
616.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 957.75B | 77.97B | 8.86% |
| Dec 31, 2023 | 879.78B | -29.18B | -3.21% |
| Dec 31, 2022 | 908.96B | -17.01B | -1.84% |
| Dec 31, 2021 | 925.98B | 67.86B | 7.91% |
| Dec 31, 2020 | 858.12B | 137.47B | 19.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| LigaChem Biosciences | 125.90B |
| PharmaResearch | 350.12B |